XERIS BIOPHARMA HOLDINGS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.37M, a 36.36% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.92M, a 66.54% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.95M, a 41.62% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.67M, a 10.32% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $16.21M, a 10.91% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $18.20M, a 69.85% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $10.72M, a 11.88% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $12.16M, a 6.84% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.37M 10-Q · filed 2026-08-06 | $12.29M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.92M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $16.21M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $3.95M 10-Q · filed 2025-11-06 | $8.62M derived: sum of 2 quarters · filed 2026-08-06 | $12.18M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $4.67M 10-Q · filed 2026-08-06 | $8.23M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.56M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $18.20M 10-K · filed 2026-03-02 | |||
| 2024-09-30 | $6.77M 10-Q · filed 2025-11-06 | $11.00M derived: sum of 2 quarters · filed 2025-11-06 | $14.77M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $4.23M 10-Q · filed 2025-11-06 | $8.00M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $3.77M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $10.72M 10-K · filed 2026-03-02 | |||
| 2023-09-30 | $2.46M 10-Q · filed 2024-11-08 | $5.38M derived: sum of 2 quarters · filed 2024-11-08 | $7.95M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $2.93M 10-Q · filed 2024-11-08 | $5.49M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $2.56M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $12.16M 10-K · filed 2025-03-06 | |||
| 2022-09-30 | $2.94M 10-Q · filed 2023-11-09 | $6.09M derived: sum of 2 quarters · filed 2023-11-09 | $9.39M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $3.15M 10-Q · filed 2023-11-09 | $6.45M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $3.30M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $11.38M 10-K · filed 2024-03-06 | |||
| 2021-09-30 | $3.67M 10-Q · filed 2022-11-09 | $6.18M derived: sum of 2 quarters · filed 2022-11-09 | $8.64M derived: sum of 3 quarters · filed 2022-11-09 | |
| 2021-06-30 | $2.51M 10-Q · filed 2022-11-09 | $4.97M derived: sum of 2 quarters · filed 2022-11-09 | ||
| 2021-03-31 | $2.46M 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $8.27M 10-K · filed 2022-03-11 | |||
| 2020-09-30 | $59.00K 10-Q · filed 2021-11-10 | $2.13M derived: sum of 2 quarters · filed 2021-11-10 | $4.14M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $2.07M 10-Q · filed 2021-11-10 | $4.08M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $2.01M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |